Eton Pharmaceuticals, Inc. (ETON)
After hours:
| Previous close | 3.7200 |
| Open | 3.7450 |
| Bid | 2.6900 x 200 |
| Ask | 4.3900 x 200 |
| Day's range | 3.3600 - 3.7500 |
| 52-week range | 2.4200 - 5.8100 |
| Volume | |
| Avg. volume | 62,145 |
| Market cap | 88.239M |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.00 |
GlobeNewswireEton Pharmaceuticals Reports First Quarter 2024 Financial Results
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth• Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400• Management to hold conference call today at 4:30pm ET DEER PARK, Ill., May 09, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commerciali
Simply Wall St.Eton Pharmaceuticals, Inc. (NASDAQ:ETON) On The Verge Of Breaking Even
We feel now is a pretty good time to analyse Eton Pharmaceuticals, Inc.'s ( NASDAQ:ETON ) business as it appears the...
- GlobeNewswire
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows: Date:Monday, May 13, 2024 Time: 10:00am ET Webcast: Click Here To schedule a 1x1 meeting with the Company, plea
